News

Feliza Mirasol is the science editor for 

Articles

AbbVie’s proposed acquisition of ImmunoGen is expected to accelerate AbbVie's entry into the commercial market for ovarian cancer and includes ImmunoGen’s flagship cancer therapy, ELAHERE (mirvetuximab soravtansine-gynx).

AbbVie to Acquire ImmunoGen in Deal Valued at $10.1 Billion

This collaboration will combine BigHat Biosciences’ AI/ML-guided Milliner platform with AbbVie's expertise in oncology and neuroscience to develop next-generation antibodies.

AbbVie Collaborates with BigHat Biosciences on Next-Gen Therapeutic Antibodies

Susan Haigney is managing editor of BioPharm International, susan.haigney@ubm.com.

AstraZeneca will utilize Absci’s AI antibody drug creation platform to create an AI-designed antibody.  

Absci and AstraZeneca Collaborate on AI-Driven Oncology Candidate

Novo Nordisk will invest more than DKK 16 billion (US$2.3 billion) to expand its production facilities in Chartres, France.

Novo Nordisk to Make Multi-Billion Dollar Investment in Expansion of Production Facilities in France

Chris Spivey is the editorial director of 

Exagamglogene autotemcel seen as synechdoche.

New Medicines, Markets, and Manufacture: CRISPR for Sickle Cell Disease and β-thalassemia

Under this multi-year collaboration, Genentech and NVIDIA will use AI to optimize and accelerate each company’s platforms to discover and develop innovative therapeutics.

Genentech and NVIDIA Form AI Research Collaboration for Drug Discovery and Development

Chris Spivey, editorial director for Pharmaceutical Technology, discusses messenger RNA (mRNA) advances with Guillaume Roelandts, Head of Products and Marketing, Quantoom Biosciences, at the 11th International mRNA Health Conference in Berlin, Germany.

Tackling Production Challenges through Greater Access to mRNA Technologies

Editor of Pharmaceutical Technology Europe

The largest biotech hub is set to be built in Lithuania by Northway Group.

Lithuania Set to Become Home to Largest Biotech City

In part two of an interview with Thomas Langenickel, MD, chief medical officer at Ethris, Langenickel highlights the challenges in developing mRNA therapeutics for pulmonary diseases.

mRNA Advances Allow Drug Development Focus on Rare Diseases (Part Two)

Under the agreement, the companies will discover and develop drug candidates targeting two ion channels linked to neurological disorders.

Biopharma News